natalizumab · Tysabri

Monoclonal antibody

Also known as BG00002

Biosimilars tracked: Tyruko (natalizumab-sztn)

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Sclerosis, Crohn's Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
JP
  • Prevention of relapse and for delaying the accumulation of physical disability in multiple sclerosis
Product first approved 2014PMDA
CA
  • TYSABRI (natalizumab) is indicated: • as monotherapy (i.e. single disease-modifying agent) for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations, to decrease the number and volume of active brain lesions identified on magnetic resonance imaging (MRI) scans and to delay the progression of physical disability. TYSABRI is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, other therapies for multiple sclerosis. Safety and efficacy in patients with chronic...
Product first approved 2006Health Canada
EU
  • Tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: Patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1) or Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant...
Product first approved 2006EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (13)
Crohn's Disease
NCT00078611 · Biogen
2004-03 – 2005-03 · Crohn's Disease
What this study did
NCT00032786 · Biogen
2002-03 – 2004-03 · Crohn's Disease
What this study did
Multiple Sclerosis
NCT04115488 · Polpharma Biologics S.A.
2019-10-01 – 2022-02-07 · Relapsing-Remitting Multiple Sclerosis (RRMS)
What this study did
NCT01416181 · Biogen
2011-09-13 – 2016-04-13 · Secondary Progressive Multiple Sclerosis
What this study did
NCT00297232 · Biogen
2006-03 – 2014-04 · Relapsing-Remitting Multiple Sclerosis
What this study did
NCT01058005 · Biogen
2010-03 – 2012-04 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT00306592 · Biogen
2006-03 – 2008-02 · Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT00276172 · Biogen
2003-12 – 2006-01 · Multiple Sclerosis
What this study did
NCT00030966 · Biogen
2002-01 – 2005-12 · Multiple Sclerosis, Relapsing-Remitting
What this study did
Phase 2/3 (1)
Multiple Sclerosis
NCT01440101 · Biogen
2010-11 – 2012-08 · Multiple Sclerosis
What this study did
Phase 2 (18)
Crohn's Disease
NCT00055367 · Biogen
2002-04 – 2004-05 · Crohn's Disease
What this study did
NCT00055536 · Biogen
2002-04 – 2003-07 · Crohn's Disease
What this study did
Multiple Sclerosis
NCT05418010 · Queen Mary University of London
2022-12-01 – 2027-10-31 · Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination
What this study did
NCT02142192 · Biogen
2014-12-01 – 2015-06-04 · Relapsing Multiple Sclerosis
What this study did
NCT01416155 · Biogen
2010-10 – 2014-12 · Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
What this study did
NCT01405820 · Biogen
2011-08 – 2014-10 · Relapsing-Remitting Multiple Sclerosis
What this study did
NCT01077466 · Copenhagen University Hospital, Rigshospitalet
2010-03 – 2012-01 · Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
What this study did
NCT01071083 · Biogen
2010-03 – 2011-11 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT00516893 · Biogen
2006-10 – 2007-12 · Multiple Sclerosis
What this study did
NCT00097760 · Biogen
2003-06 – 2004-03 · Multiple Sclerosis, Relapsing-Remitting
What this study did
Other / comorbidity
NCT07892027 · University of Michigan Rogel Cancer Center
2026-11-10 – 2028-05-01 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma
What this study did
NCT02133924 · John Levine
2016-08 – 2021-11-21 · Acute Graft Versus Host Disease
What this study did
NCT03283371 · Biogen
2018-03-20 – 2020-11-18 · Epilepsy, Focal Seizures, Partial Seizures
What this study did
NCT02176031 · Dana-Farber Cancer Institute
2015-01 – 2019-02 · Graft Versus Host Disease
What this study did
NCT02730455 · Biogen
2016-07-18 – 2017-11-20 · Acute Ischemic Stroke
What this study did
NCT01955707 · Biogen
2014-01 – 2015-04 · Acute Ischemic Stroke
What this study did
NCT00083759 · Biogen
2004-05 – 2005-02 · Rheumatoid Arthritis
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT03811886 · Case Comprehensive Cancer Center
2024-12-01 – 2026-10-01 · Pulmonary Metastatic Osteosarcoma (pOS)
What this study did
NCT00675428 · Biogen
2008-09 – 2009-12 · Multiple Myeloma
What this study did
Phase 1 (6)
Multiple Sclerosis
NCT01884935 · Biogen
2013-07 – 2014-09 · Relapsing-Remitting Multiple Sclerosis
What this study did
NCT00559702 · Biogen
2007-10 – 2011-11 · Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
What this study did
NCT00424788 · Biogen
2007-01 – 2007-10 · Relapsing Forms of Multiple Sclerosis
What this study did
Other / comorbidity
NCT05618301 · Washington University School of Medicine
2023-07-07 – 2025-06-24 · Sickle Cell Disease
What this study did
NCT03093064 · King's College London
2017-04-01 – 2023-08-07 · Schizophrenia
What this study did
NCT02483845 · Phoenix Neurological Associates, LTD
2013-05 – 2017-11 · Inclusion Body Myositis (IBM)
What this study did
Phase 4 (22)
Crohn's Disease
NCT00801125 · Biogen
2008-12 – 2010-05 · Crohn's Disease
What this study did
NCT00280956 · Biogen
2002-07 – 2004-09 · Crohn's Disease
What this study did
Multiple Sclerosis
NCT04225312 · Amsterdam UMC, location VUmc
2020-02-03 – 2025-03-01 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT02769689 · University Hospital, Clermont-Ferrand
2019-06-12 – 2024-07-20 · Multiple Sclerosis
What this study did
NCT03046251 · State University of New York at Buffalo
2015-08 – 2023-12 · Multiple Sclerosis
What this study did
NCT05177718 · Vanderbilt University Medical Center
2022-09-16 – 2023-04-05 · Multiple Sclerosis
What this study did
NCT04048577 · Berkovich, Regina MD, PhD Inc.
2019-07-03 – 2021-12-01 · Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT02904876 · University Hospital, Strasbourg, France
2015-03 – 2020-05 · Multiple Sclerosis
What this study did
NCT03516526 · Amsterdam UMC, location VUmc
2016-11-03 – 2019-07-01 · Multiple Sclerosis
What this study did
NCT02342704 · Biogen
2014-11-30 – 2016-05-18 · Relapsing-Remitting Multiple Sclerosis
What this study did
NCT02241785 · Biogen
2014-09-30 – 2016-05-02 · Relapsing Multiple Sclerosis
What this study did
NCT02325440 · University Hospital Muenster
2014-03 – 2016-04 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT02775110 · University at Buffalo
2012-11 – 2014-03 · Multiple Sclerosis
What this study did
NCT02142205 · Biogen
2012-05 – 2013-12 · Relapsing-Remitting Multiple Sclerosis
What this study did
NCT01591551 · Cornerstone Health Care, PA
2012-03 – 2013-08 · Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT00752778 · University Hospital, Strasbourg, France
2008-12 – 2011-03 · Multiple Sclerosis
What this study did
NCT00942214 · University Hospital, Toulouse
2009-06 – 2011-03 · Multiple Sclerosis
What this study did
NCT00771043 · Biogen
2008-11-01 – 2010-06-01 · Relapsing-remitting Multiple Sclerosis
What this study did
NCT00536120 · Biogen
2008-01 – 2009-12 · Multiple Sclerosis
What this study did
NCT00744679 · Biogen
2008-11 – 2008-12 · Multiple Sclerosis
What this study did
Early phase / not applicable (4)
Multiple Sclerosis
NCT03500328 · Johns Hopkins University
2018-05-02 – 2026-08-31 · Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT05172466 · Icahn School of Medicine at Mount Sinai
2022-10-31 – 2022-11-11 · Relapsing-remitting Multiple Sclerosis (RRMS)
What this study did
NCT01071512 · University of Chicago
2010-04 – 2016-01 · Multiple Sclerosis
What this study did
NCT01455220 · University of South Florida
2011-01 – 2014-10 · Multiple Sclerosis
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 4 (1)
Multiple Sclerosis
NCT01144052 · Claudio Gobbi
2010-06 – 2011-11 · Relapsing-remitting Multiple Sclerosis
What this study did
Early phase / not applicable (1)
Multiple Sclerosis
NCT01065727 · Rennes University Hospital
2010-03 – 2023-11 · Multiple Sclerosis
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Multiple Sclerosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Natalizumab (Tysabri): this drugApprovedMonoclonal antibodyα4 integrinReliable signal
NCT00027300: Sustained disability progression at 2 years reduced 42% (hazard ratio 0.58, 95% CI 0.43-0.77, P<0.001; cumulative probability 17% natalizumab vs 29% placebo); clinical relapse rate at 1 year reduced 68% (P<0.001).
NCT03689972: Part 1: Mean Number of New or Newly Enlarging T2 Hyperintense Lesions at Week 72 (Week 72): Part 1: IV Q4W 0.05 number of T2 lesions (95% CI 0.01 to 0.22) | Part 1: IV Q6W 0.2 number of T2 lesions (95% CI 0.07 to 0.63)
AlemtuzumabApprovedMonoclonal antibodyCD52Partial signal
NCT00930553: Annualized Relapse Rate (ARR) (Year 3, 4, 5, 6 from the Baseline (Month 0 of CAMMS323 and Month 0 of CAMMS324 for "Alemtuzumab Treatment CAMMS323 Extension" group and "Alemtuzumab Treatment CAMMS324 Extension" group, respectively)): Alemtuzumab Treatment CAMMS323 Extension — Year 3: 0.19 relapses per participant per year; Year 4: 0.16 relapses per participant per year; Year 5: 0.15 relapses per participant per year; Year 6: 0.12 relapses per participant per year | Alemtuzumab Treatment CAMMS324 Extension — Year 3: 0.22 relapses per participant per year; Year 4: 0.24 relapses per participant per year; Year 5: 0.19 relapses per participant per year; Year 6: 0.16 relapses per participant per year
NCT00548405: Percentage of Participants With Sustained Accumulation of Disability (SAD) (Up to 2 years): Alemtuzumab 12 mg 12.71% (95% CI 9.89 to 16.27) vs Interferon Beta-1a 21.13% (95% CI 15.95 to 27.68)
BafiertamApprovedSmall moleculeNrf2 pathway (fumaric acid ester)not yet gradedNo reviewed efficacy summary in this indication
Cladribine (MAVENCLAD®)ApprovedSmall moleculeAdenosine deaminase-resistant purine analog, DNA synthesis machinery in lymphocytesReliable signal
NCT00213135: Annualized Qualifying Relapse Rate (Week 96): Cladribine 5.25 mg/kg 0.15 relapses per year (95% CI 0.12 to 0.17) | Cladribine 3.5 mg/kg 0.14 relapses per year (95% CI 0.12 to 0.17) vs Placebo 0.33 relapses per year (95% CI 0.29 to 0.38)
CopaxoneApprovedPeptideMyelin basic protein-mimetic immunomodulationnot yet gradedNo reviewed efficacy summary in this indication
Dimethyl Fumarate (Tecfidera)ApprovedSmall moleculeNrf2 pathway (fumaric acid ester)Reliable signal
NCT00451451: Adjusted annualized relapse rate at 2 years: 0.224 relapses/year (95% CI 0.179–0.282) with BG00012 240 mg BID vs 0.401 (95% CI 0.329–0.488) with placebo; 0.198 (95% CI 0.156–0.252) with BG00012 240 mg TID vs 0.401 (95% CI 0.329–0.488) with placebo.
NCT00420212: Estimated proportion relapsed by 2 years: 27% with BG-12 240 mg twice daily and 26% with 240 mg three times daily vs 46% with placebo (P<0.001 for both comparisons) (DEFINE, N Engl J Med 2012).
Diroximel Fumarate (Vumerity)ApprovedSmall moleculeNrf2 pathway (fumaric acid ester)Weak signal
NCT03093324: Primary GI symptom days: mean 1.5 (SD 2.85) with ALKS 8700 vs 2.5 (SD 4.68) with dimethyl fumarate; rate ratio 0.542 (95% CI 0.390-0.754), p=0.0003.
Fampridine (Ampyra / Fampyra)ApprovedSmall moleculePotassium Channel Blocker, Voltage-gated potassium channel (Kv), Voltage-gated potassium channels (Kv1/Shaker/KCNA family)Partial signal
NCT00127530: Timed walk responders: fampridine 78/224 (35%) vs placebo 6/72 (8%), p<0.0001 (Goodman et al., Lancet 2009)
Fingolimod (Gilenya)ApprovedSmall moleculeSphingosine 1-phosphate receptor (S1PR, specifically S1P1), S1P receptor, Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)Reliable signal
NCT00289978: Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Fingolimod 1.25 mg 0.16 Relapses per year (95% CI 0.13 to 0.19) | Fingolimod 0.5 mg 0.18 Relapses per year (95% CI 0.15 to 0.22) vs Placebo 0.4 Relapses per year (95% CI 0.34 to 0.47)
NCT00340834: Annualized relapse rate over 12 months: fingolimod 1.25 mg 0.20 (95% CI 0.16 to 0.26) and 0.5 mg 0.16 (95% CI 0.12 to 0.21) vs interferon beta-1a IM 0.33 (95% CI 0.26 to 0.42); p<0.001 for both comparisons. n=1,292 randomized (TRANSFORMS, Cohen 2010, NEJM).
Interferon Beta-1a (Avonex)ApprovedBiologic (subtype unspecified)Type I Interferon receptor (IFNAR)Weak signal
NCT00211887: ARR - PDEs (Baseline to Month 36): IFN + GA 0.12 relapses per year | IFB-1a 0.16 relapses per year vs Glatiramer 0.11 relapses per year
Interferon Beta-1bApprovedBiologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptorPartial signal
NCT00185211: Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment): Initial IFNB-1b (Interferon Beta-1b) — Kaplan-Meier estimate at year 2: 26.9 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 36.7 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 46.2 cum. percentage of particip. with CDMS vs Initial Placebo — Kaplan-Meier estimate at year 2: 45 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 51.2 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 57.3 cum. percentage of particip. with CDMS
NCT00099502: Enrolled 897 (250mcg) + 899 (500mcg) + 448 (glatiramer acetate) = 2244 patients (matches this trial's enrollment). Annualized relapse rate 0.33-0.36 across arms; no statistically significant difference in relapse/progression measures between the 500mcg and 250mcg IFN beta-1b doses, or vs glatiramer acetate. missed
OcrelizumabApprovedMonoclonal antibodyCD20Partial signal
NCT05123703: Protocol-defined annualized relapse rate: ocrelizumab 0.070 vs fingolimod 0.135; adjusted rate ratio 0.517 (95% CI 0.193 to 1.329), non-inferiority analysis (CT.gov posted results); Roche states non-inferiority to fingolimod with a 48% lower relapse risk.
NCT01247324: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks (Week 96): Interferon Beta-1a 44 mcg SC 0.292 relapses/participant year of treatment (95% CI 0.235 to 0.361) | Ocrelizumab 0.156 relapses/participant year of treatment (95% CI 0.122 to 0.2)
Ocrevus ZunovoApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
OfatumumabApprovedMonoclonal antibodyCD20Reliable signal
NCT02792231: Annualized Relapse Rate (ASCLEPIOS II): 0.10 (ofatumumab) vs 0.25 (teriflunomide); difference -0.15 (95% CI: -0.20, -0.09)
NCT02792218: Annualized relapse rate (median 1.6-year follow-up): 0.11 ofatumumab vs 0.22 teriflunomide; difference -0.11 (95% CI -0.16 to -0.06).
Ozanimod (Zeposia)ApprovedSmall moleculeS1P receptorPartial signal
NCT02047734: Adjusted annualized relapse rate (ARR) over 24 months (RADIANCE): 0.17 ozanimod 1.0mg, 0.22 ozanimod 0.5mg, vs 0.28 interferon beta-1a; rate ratio vs interferon 0.62 (p<0.0001) for the 1.0mg dose and 0.79 (p=0.0167) for the 0.5mg dose
NCT02294058: Adjusted Annualized Relapse Rate (ARR) During the Treatment Period (12 months): Ozanimod 0.5 mg 0.241 relapses/year (95% CI 0.188 to 0.308) | Ozanimod 1 mg 0.181 relapses/year (95% CI 0.14 to 0.236) vs Interferon Beta-1a 0.35 relapses/year (95% CI 0.279 to 0.44)
Peginterferon Beta-1a (Plegridy)ApprovedBiologic (subtype unspecified)Type I interferon receptor, Interferon beta receptor (type I IFN signaling)Reliable signal
NCT00906399: Annualized Relapse Rate (ARR) at 1 Year (1 Year): Year 1: Peginterferon Beta-1a Q4W 0.288 relapses per person-years (95% CI 0.234 to 0.355) | Year 1: Peginterferon Beta-1a Q2W 0.256 relapses per person-years (95% CI 0.206 to 0.318) vs Year 1: Placebo 0.397 relapses per person-years (95% CI 0.328 to 0.481)
NCT01939002: New or increased FLS during the first 8 weeks: 10.3% overall versus 25% null (p<0.0001); current FLS therapy 13% versus naproxen 7.4% (p=0.2037).
PonesimodApprovedSmall moleculeS1P receptorReliable signal
NCT02425644: Annualized relapse rate at week 108: 0.202 ponesimod vs 0.290 teriflunomide; rate ratio 0.695 (99% CI 0.536-0.902); 30.5% relative reduction; P<.001.
Rebif (interferon Beta 1a)ApprovedBiologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptorWeak signalFeatured results are non-efficacy only in this race
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)Weak signalFeatured results are non-efficacy only in this race
Siponimod (Mayzent)ApprovedSmall moleculeS1P receptorWeak signal
NCT01665144: EXPAND (n=1,651), primary endpoint 3-month confirmed disability progression on EDSS: 26.3% with siponimod vs 31.7% with placebo; HR 0.79 (95% CI 0.65 to 0.95), Cox model p=0.0134 (CT.gov posted results).
Tascenso ODTApprovedSmall moleculeS1P receptornot yet gradedNo reviewed efficacy summary in this indication
Teriflunomide HMR1726 (Aubagio)ApprovedSmall moleculeDihydroorotate dehydrogenase (DHODH)Reliable signal
NCT03122652: Time to first clinical demyelinating event: unadjusted HR 0.37 (95% CI 0.16-0.84; P=.02), adjusted HR 0.28 (95% CI 0.11-0.71; P=.007), teriflunomide vs placebo (63% unadjusted / 72% adjusted risk reduction)
NCT00751881: Annualized relapse rate (core period): placebo 0.501, teriflunomide 7 mg 0.389 (relative reduction 22.3%, p=0.0183), 14 mg 0.319 (relative reduction 36.3%, p=0.0001); step-down testing, 14 mg first (CT.gov posted results).
Tyruko (natalizumab-Sztn)ApprovedMonoclonal antibodyα4 integrinnot yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)ApprovedMonoclonal antibodyCD20Reliable signal
NCT03277248: Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.091 relapses per participant-years (95% CI 0.049 to 0.169) vs Teriflunomide + IV Placebo 0.178 relapses per participant-years (95% CI 0.109 to 0.291)
NCT03277261: Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.076 relapses per participant-years (95% CI 0.042 to 0.138) | Teriflunomide + IV Placebo 0.188 relapses per participant-years (95% CI 0.124 to 0.283)
ABP 692Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
BCD-281Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
CT-P53Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Divozilimab (Ivlizi)Phase 3Monoclonal antibodyCD20Reliable signal
NCT05385744: Annualised relapse rate over 2 years (100 weeks): divozilimab 0.057 vs teriflunomide 0.164
FenebrutinibPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
FrexalimabPhase 3Monoclonal antibodyCD40 ligand (CD40L / CD154)not yet gradedNo reviewed efficacy summary in this indication
Nabiximols (Sativex)Phase 3BotanicalCannabinoid CB1/CB2 receptors (agonist)Partial signal
NCT04657666: Change From Baseline in Lower Limb Muscle Tone-6 (LLMT-6) (Baseline (predose Day 1 of Treatment Period 1) up to Day 51 (end of treatment of Treatment Period 2)): Nabiximols -0.23 units on a scale (Standard Error 0.07) vs Placebo -0.26 units on a scale (Standard Error 0.07) missed
NCT01610700: Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at the End of 6 Weeks of Treatment (baseline and 6 weeks): GW-1000-02 -25.32 units on a scale (Standard Deviation 23.42) vs Placebo -19.32 units on a scale (Standard Deviation 27.02) missed
RemibrutinibPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
TolebrutinibPhase 3Small moleculeBruton's tyrosine kinase (BTK)Reliable signal
NCT04411641: HERCULES (n=1,131, nrSPMS), primary endpoint time to onset of 6-month confirmed disability progression on EDSS: tolebrutinib 60 mg vs placebo HR 0.693 (95% CI 0.546 to 0.880), Cox regression p=0.0026 (CT.gov posted results).
NCT04458051: 6-month composite confirmed disability progression (cCDP), tolebrutinib vs placebo: HR 1.01 (95% CI 0.81-1.26), p=.94 — no difference from placebo. missed
Vidofludimus CalciumPhase 3—Dihydroorotate dehydrogenase (DHODH)not yet gradedNo reviewed efficacy summary in this indication
CNM-Au8Phase 2/3Nanoparticlemitochondrial energy metabolismPartial signal
NCT04626921: LCLA (Best-Corrected Low-Contrast Letter Acuity) change across both eyes at Week 144 vs original randomization baseline, CNM-Au8 arm: least-squares mean difference +8.70 letters (SE 1.88), 95% CI 5.0 to 12.4, p<0.0001
CorubrutinibPhase 2Small moleculeBruton's tyrosine kinase (BTK)Partial signal
NCT05798520: Biogen reported that BIIB091 achieved proof-of-concept in relapsing-remitting MS (no figures released)
ForalumabPhase 2Monoclonal antibodyCD3not yet gradedNo reviewed efficacy summary in this indication
IrafamdastatPhase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
A-005
Phase 1(overall)
Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
AZD0120Phase 1Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
Azercabtagene Zapreleucel
Phase 1(overall)
Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
IDP-023Phase 1Cell therapyAllogeneic g-NK cell therapynot yet gradedNo reviewed efficacy summary in this indication
RG6035
—(overall)
Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
RG6182
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
BaminerceptDiscontinuedProtein / enzyme therapeuticLymphotoxin-beta receptor (LTβR)not yet gradedNo reviewed efficacy summary in this indication
Firategrast (SB-683699)DiscontinuedSmall moleculeVLA-4 (integrin alpha-4/beta-1), Integrin alpha-4 (ITGA4)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tysabri (natalizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
Phase 2Multiple SclerosisRecruiting
Est. primary completion 2027-10-31 · NCT05418010 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
Phase 2Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma …Recruiting
Est. primary completion 2028-05-01 · NCT07892027 · CT.gov ↗
What to watch

See the full readout calendar ↗